Stereotactic Radiosurgery/TKIs Improves CNS Outcomes in EGFR/ALK+ NSCLC
Patients with non–small cell lung cancer and larger brain metastases may benefit most from the addition of up-front stereotactic radiosurgery to TKIs.
FDA Approves Inavolisib Combo in PIK3CA+ Advanced Breast Cancer
Data from the INAVO120 trial support the approval of the inavolisib combination for those with PIK3CA-mutant breast cancer.
Overcoming Barriers to Trial Enrollment and Gaps in Gynecologic Cancer Care
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Talazoparib/Enzalutamide Combo Prolongs Survival in Metastatic CRPC
Detailed results from the phase 3 TALAPRO-2 trial will be submitted for presentation at a future medical meeting and shared with global health authorities.
Durvalumab Shows Manageable Safety Profile in LS-SCLC
Results showed of the phase 3 ADRIATIC study found that treatment with durvalumab elicited similar radiation pneumonitis incidences vs placebo for LS-SCLC.
Advancing Prevention and Genetic Testing Methods in Uterine Cancer
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
TAR-200 Study in Muscle-Invasive Bladder Cancer Discontinued
TAR-200 plus cetrelimab did not yield significant results vs chemoradiation in muscle-invasive bladder cancer.
Raising Awareness to Address the Rising Incidence of Gynecologic Cancers
Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.
Gene Expression Test May Predict Added Atezolizumab Benefit in TNBC
Phase 2 data indicate that the use of DetermaIO was predictive of a pathologic complete response with the addition of immunotherapy to chemotherapy in TNBC.
Post-Transplant Daratumumab Combo Increases MRD Negativity in NDMM
Data support the addition of daratumumab to standard lenalidomide maintenance in patients with newly diagnosed multiple myeloma following transplant.
Ongoing Consolidative RT Trial May Support Efficacy Findings in SCLC
James Ninia, MD, discussed a phase 2/3 trial seeking to answer whether complete consolidation offers more benefit than incomplete consolidation in SCLC.
Uterine Transposition Surgery Improves QOL Through Fertility Preservation
A new surgical option of uterine transposition may help preserve fertility for women who have cancers of the pelvic region.
PFS Benefit Occurs with Complete vs Incomplete Consolidative RT in ES-SCLC
Overall survival benefit was significant with complete vs incomplete consolidation therapy, but lost significance when stratified by disease burden.
Perioperative Pembrolizumab Combo Improves EFS in Locally Advanced HNSCC
Data also show an improvement in major pathological response in the perioperative pembrolizumab arm of the KEYNOTE-689 trial.
Assessing Consolidative Radiation in Extensive-Stage Small Cell Lung Cancer
James Ninia, MD, discussed treatment options for patients with extensive-stage small cell lung cancer undergoing metastasis-directed radiotherapy.
Neoadjuvant/Adjuvant Pembrolizumab Combo Improves OS in NSCLC
Results from KEYNOTE-671 show an improvement in OS when a neoadjuvant/adjuvant regimen of pembrolizumab was used to treat patients with NSCLC.
Data Show Disease Control With Inavolisib in Advanced PIK3CA+ Solid Tumors
Investigators are currently assessing possible predictors for response to inavolisib as part of the phase 2 CRAFT trial.
Durcabtagene Autoleucel Yields Responses in Relapsed/Refractory Myeloma
Treatment with durcabtagene autoleucel meets the primary end point of a phase 2 study in relapsed/refractory multiple myeloma.
BLA Submitted for Teliso-V in Advanced EGFR Wild-type NSCLC
Data from the LUMINOSITY trial support the application for telisotuzumab vedotin in nonsquamous NSCLC harboring c-Met protein overexpression.
Ultra-Hypofractionated RT May Offer Convenience in Elderly Breast Cancer
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Forming Connections and Making a Difference in the Brain Cancer Field
The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.
Ultra-Hypofractionated Radiation May Mitigate Breast Cancer Recurrence
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
Elacestrant Combo Shows Activity, Tolerability in Metastatic Breast Cancer
Investigators report no grade 4 adverse effects among patients who received elacestrant/abemaciclib in the phase 1b/2 ELECTRA trial.
Exploring the Use of Ultra-Hypofractionated RT in Elderly Breast Cancer
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Novel BCL-2 Inhibitor Combo Shows Enduring Responses in R/R Myeloma Subtype
Data from a phase 1b/2 trial show that sonrotoclax/dexamethasone appears to be well tolerated in a heavily pretreated multiple myeloma population.
Quadruplet Therapy Shows Benefit for Newly Diagnosed Multiple Myeloma
Thomas G. Martin, MD, discussed the advantages of quadruplet therapy for multiple myeloma in light of an FDA approval for Isa-VRd in this indication.
Nivolumab/RT Improves Biochemical Recurrence Outcomes in Prostate Cancer
Phase 2 data support further evaluation of nivolumab plus standard radiotherapy in patients with Gleason grade 5 prostate cancer.
FDA Approves Noninvasive Stool DNA Test for Colorectal Cancer Screening
Data from the BLUE-C trial support the approval of the Cologuard Plus test for colorectal cancer screening among at-risk individuals.
Isatuximab Combo Yields MRD-Negative Responses in Transplant-Eligible NDMM
Nearly all patients in the per-protocol population of the MIDAS study achieved a very good partial response or better following study treatment.
Daratumumab Combo Yields MRD-Negative Status in Transplant-Ineligible NDMM
Phase 3 data support a daratumumab-based quadruplet as a new potential regimen in transplant-ineligible newly diagnosed multiple myeloma.
